Epidemiology of mucormycosis in Europe.

Zygomycosis (mucormycosis) is being increasingly recognized as causing infection in recent years. National and multinational European surveys attempting to analyse the epidemiological parameters of this potentially devastating infection are very few. Although the exact incidence could not be defined due to the different methodologies used in these studies and the absence of a denominator, there were some useful observations made regarding the clinical presentation, sites of infection and diagnostic practices. Moreover, the importance for a prompt and accurate diagnosis has been stressed. As early diagnosis can significantly affect the initiation of treatment and decrease mortality, future research should focus on the development of an epidemiological risk assessment tool and novel diagnostic methods.

[1]  D. Horn,et al.  Prospective antifungal therapy (PATH) alliance®: focus on mucormycosis , 2014, Mycoses.

[2]  C. Elie,et al.  A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  P. Hamal,et al.  Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[4]  V. Saegeman,et al.  Increasing Incidence of Mucormycosis in University Hospital, Belgium , 2010, Emerging infectious diseases.

[5]  J. Garbino,et al.  Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[6]  A. Simon,et al.  Forty-one recent cases of invasive zygomycosis from a global clinical registry. , 2009, The Journal of antimicrobial chemotherapy.

[7]  J. Desenclos,et al.  Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006 , 2009, Emerging infectious diseases.

[8]  C. Romano,et al.  Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed Animale and European Confederation of Medical Mycology) , 2009, Journal of chemotherapy.

[9]  E. Anaissie,et al.  Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Mellado,et al.  In vitro activity of antifungals against Zygomycetes. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  G. Samonis,et al.  Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices? , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  C. Lass‐Flörl Zygomycosis: conventional laboratory diagnosis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  D. Kontoyiannis,et al.  Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  T. Peláez,et al.  Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. , 2008, Medical mycology.

[16]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  F. Marty,et al.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. , 2004, The New England journal of medicine.

[18]  N. Katsilambros,et al.  Mucormycosis: Ten-Year Experience at a Tertiary-Care Center in Greece , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[19]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Pinner,et al.  The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.